Authors/Disclosures
|
Harald Hegen, MD
|
Dr. Hegen has nothing to disclose. |
|
Corrado Angelini, MD, FAAN
(Università Di Padova)
|
Dr. Angelini has nothing to disclose. |
|
|
No disclosure on file |
|
Claudia Gneiss
(Universitäts-Klinik für Neurologie)
|
No disclosure on file |
|
Markus Reindl, PhD
(Medical University of Innsbruck)
|
The institution of Dr. Reindl has received research support from Euroimmun. The institution of Dr. Reindl has received research support from Roche. |
|
Florian Deisenhammer, MD
|
Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Deisenhammer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS/Celgene. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Almirall. Dr. Deisenhammer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Celgene. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Deisenhammer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SOBI. |
|
Charles S. DeCarli, MD, FAAN
(UC Davis Health - Dept of NeurologyAlzheimer's Disease Research Center)
|
Dr. DeCarli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. The institution of Dr. DeCarli has received research support from NIH. |